Nisa Investment Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-736
| Closed | -$75K | – | 2867 |
|
|
2023
Q2 | $75K | Sell |
736
-5
| -0.7% | -$473 | ﹤0.01% | 1601 |
|
|
2023
Q1 | $67K | Buy |
741
+490
| +195% | +$28.8K | ﹤0.01% | 1626 |
|
|
2022
Q4 | $10K | Buy |
251
+6
| +2% | +$206 | ﹤0.01% | 2215 |
|
|
2022
Q3 | $8K | Sell |
245
-65
| -21% | -$1.8K | ﹤0.01% | 2239 |
|
|
2022
Q2 | $9K | Sell |
310
-17,079
| -98% | -$510K | ﹤0.01% | 2207 |
|
|
2022
Q1 | $570K | Sell |
17,389
-889
| -5% | -$26.4K | ﹤0.01% | 1037 |
|
|
2021
Q4 | $514K | Buy |
18,278
+16,529
| +945% | +$1.28M | ﹤0.01% | 1005 |
|
|
2021
Q3 | $176 | Sell |
1,749
-739
| -30% | -$86.6K | ﹤0.01% | 1451 |
|
|
2021
Q2 | $352 | Sell |
2,488
-430
| -15% | -$48.6K | ﹤0.01% | 1233 |
|
|
2021
Q1 | $291 | Buy |
2,918
+1,200
| +70% | +$140K | ﹤0.01% | 1356 |
|
|
2020
Q4 | $212K | Buy |
1,718
+635
| +59% | +$83.4K | ﹤0.01% | 1445 |
|
|
2020
Q3 | $106K | Sell |
1,083
-1,159
| -52% | -$145K | ﹤0.01% | 1529 |
|
|
2020
Q2 | $350K | Buy |
2,242
+1,219
| +119% | +$185K | ﹤0.01% | 1142 |
|
|
2020
Q1 | $148K | Buy |
1,023
+20
| +2% | +$3.86K | ﹤0.01% | 1269 |
|
|
2019
Q4 | $205K | Sell |
1,003
-427
| -30% | -$77.9K | ﹤0.01% | 1321 |
|
|
2019
Q3 | $115K | Buy |
1,430
+1,280
| +853% | +$109K | ﹤0.01% | 1430 |
|
|
2019
Q2 | $14K | Hold |
150
| – | – | ﹤0.01% | 1674 |
|
|
2019
Q1 | $13K | Buy |
+150
| New | +$12.5K | ﹤0.01% | 1696 |
|
Other funds holding RETA
Nisa Investment Advisors's RETA Position: Q3 2023 in Review
Nisa Investment Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 736 shares — an estimated $75K sold.
Nisa Investment Advisors first reported a position in RETA in Q1 2019 and held it in 18 quarters. The position peaked at $570K in Q1 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Nisa Investment Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Nisa Investment Advisors sold 736 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $75K.
- Nisa Investment Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 18 quarters.
- Nisa Investment Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $570K in Q1 2022.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Nisa Investment Advisors's 13F filing for Q3 2023, filed 2 Nov 2023.